MUMBAI / ATLANTA – In a strategic move to strengthen its global supply chain and deepen its roots in a key market Mumbai-based ACG a world leader in integrated pharmaceutical solutions, is making a phased $200 million investment to establish its first empty-capsule manufacturing operation in the United States.
The new facility, to be built in Atlanta, Georgia is designed to bring production closer to its North American customers, ensuring faster delivery, enhanced collaboration, and a more resilient supply chain for critical pharmaceutical components.
A Phased Investment for Long-Term Growth
The investment will be rolled out in two distinct phases:
- Phase 1: An initial $100 million will fund the construction of a state-of-the-art hard-shell capsule manufacturing plant.
- Phase 2: A subsequent $100 million will be allocated to expand the facility’s capacity and capabilities.
This project is expected to create more than 200 jobs in the Atlanta region, with operations targeted to commence in early 2027.
Strengthening Ties and De-risking the Supply Chain
For over 25 years, ACG has been a major supplier to the North American pharmaceutical market. This new local manufacturing base represents a significant evolution of that relationship.
Karan Singh, ACG Managing Director, explained, “This facility strengthens our ties with customers… bringing us closer to them, enabling faster lead times, higher-quality service, and a more resilient, de-risked supply chain. Just as importantly, it lets us respond more quickly and co-develop new innovations through tighter R&D partnerships.”
The facility will include dedicated production lines for both gelatin and vegetarian (HPMC) hard-shell capsules, adhering to the highest global standards of quality and regulatory compliance.
Why Atlanta Was the Chosen Hub
The selection of Atlanta was a strategic decision based on the city’s robust infrastructure and business-friendly environment.
Selwyn Noronha, CEO of ACG Capsules, stated, “Atlanta is the right location to execute at scale. Georgia and the City of Atlanta offer a pro-business environment, a strong talent pipeline, world-class connectivity, and reliable infrastructure.”
This new US plant joins ACG’s recent global expansions, including new facilities in Aurangabad (India), Thailand, Brazil, and Croatia, demonstrating the company’s disciplined approach to building a reliable, worldwide manufacturing network.
Frequently Asked Questions (FAQ).
1. What does ACG manufacture?
ACG is a leading global manufacturer of empty hard-shell capsules (both gelatin and vegetarian) and provides integrated solutions for the solid-dosage pharmaceutical industry.
2. Where is the new US facility located?
The new capsule manufacturing plant will be built in Atlanta, Georgia, USA.
3. What is the total investment value?
ACG is making a total investment of $200 million, to be deployed in two phases of $100 million each.
4. When will the plant be operational?
The company is targeting the start of operations for early 2027.
5. How many jobs will this create?
The project is expected to create more than 200 new jobs in the Atlanta area.
6. Why is ACG building a plant in the US?
The primary reasons are to reduce delivery times, provide a more resilient and de-risked supply chain for its North American customers, and foster closer R&D collaborations for new product innovation.
7. What types of capsules will be produced?
The facility will be equipped to manufacture both gelatin-based and vegetarian (HPMC) hard-shell capsules.
